TELK's Telintra (ezatiostat hydrochloride) has shown to induce cellular death in leukemia cells while simultaneously aiding in new bone marrow and blood cell production. In the phase II clinical trial extended dosing of Telintra was found to improve blood cell counts reducing dependence on red blood cell transfusions in patients with myelodysplatic syndrome.
Real interesting is the fact Celgene's Revlimid (lenalidomide) in combination with Telintra is effective and safe in low - risk MDS patients. Potential partnering here. These findings are published in the Journal of Hematology and Oncology.
The American Cancer Society says 20,000 new cases of MDS are diagnosed in just the United States each year.
GlobalData found that there is a high unmet need, implying the market is not served well with current treatment options.
Shorts and those who want your shares would have you confuse a past failed trial of Telcyta with Telintra.
This time around management is not making the same mistake.
Telik's pipeline has several pre-clinical drugs however they are now focusing on Telintra.
Remember most patients initially respond to treatment with granulocyte colony stimulating factors, G-CSF; however some fail to respond while many others become resistant to G-CSF treatment. G-CSF treatment is associated with bone and muscle pain, low platelet counts and enlargement of the spleen. These side effects interfere with therapy.
Myelodysplastic syndrome (MDS), is a form of pre-leukemia in which the bone marrow produces insufficient levels of one or more of the 3 major blood elements (white blood cells, red blood cells and platelets) and may ultimately progress to leukemia.
TELINTRA® treatment was associated with improvement in all three types of blood cells in patients with all types of MDS, including those in intermediate and high-risk groups
In short, all development stage biotech company shares present some degree of risk in investment. TELK at present is significantly undervalued relative to its cohorts. TELK at the present valuation is more than just a buy; it may be an aggressive buy.
Celgene’s Global Revlimid Sales Total $2.47 Billion In 2010 – Up 45%
Revlimid (lenalidomide) in combination with Telintra is effective and safe in low - risk MDS patients. Potential partnering here. These findings are published in the Journal of Hematology and Oncology.
Here's what one big drug can do: Celgene announced that it expects fiscal 2007 profits to double to $1.05 per share, as sales of its cancer drug Revlimid skyrocket. And the company projects that Revlimid will be its profit engine for 2008 as well.
Overall revenue for the company shot up by 50 percent to $1.4 billion; Revlimid's sales grew by a whopping 140 percent to $770 million-plus. As the juggernaut rolls forward, profits should grow a further 45 percent to $1.50 to $1.55 per share on a 30 percent hike in sales to $1.8 billion. And Revlimid will account for 60 percent of that figure, or about $1.25 billion.
Analysts are even more bullish on the company: They're projecting 2008 sales of more than $2 billion. The lion's share of that would come from Revlimid, though Celgene will add another blood-cancer treatment to its quiver when its buyout of Pharmion--and its drug Vidaza--closes later this year.